What is Vilya?
Vilya operates as a specialized computational biotechnology firm, co-founded by a team of distinguished scientists from the Institute of Protein Design (IPD), including David Baker, Ph.D. The company is fundamentally redefining the landscape of medicine by exploring uncharted chemical space within cyclic peptides. By utilizing sophisticated computational platforms, Vilya designs novel molecular structures that do not exist in nature, effectively creating a new class of therapeutics. This strategic focus on protein design allows the company to target disease pathways that were previously considered undruggable, establishing a robust competitive advantage in the life sciences market.
How much funding has Vilya raised?
Vilya has raised a total of $71M across 1 funding round:
Series A
$71M
Series A (2024): $71M with participation from Madrona Venture Group, NVentures, ARCH Venture Partners, and Menlo Ventures
Key Investors in Vilya
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Menlo Ventures
Menlo Ventures is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology companies across sectors such as enterprise software, consumer internet, fintech, infrastructure, and frontier tech.
Madrona Venture Group
Founded in 1995, Madrona Venture Group is a venture capitalist investment company including consumer internet, commercial software, and services.
What's next for Vilya?
With the recent influx of capital, Vilya is well-positioned to accelerate its research and development pipeline, transitioning from foundational computational modeling to the practical application of its cyclic peptide platform. The company's strategic roadmap involves scaling its proprietary technology to validate its molecular designs in clinical settings. As Vilya continues to bridge the gap between advanced computing and biological application, the firm is expected to attract further interest from institutional investors looking to capitalize on the convergence of artificial intelligence and drug discovery. The focus remains on transforming the pharmaceutical industry's approach to medicine, with the ultimate goal of delivering curative solutions for high-unmet-need diseases.
See full Vilya company page
